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1. Introduction  
Cytokines and other biological compounds are considered as future drugs and they are of 
particular interest for the treatment of chronic diseases. These endogenous compounds, that 
normally mediate local cellular communications, are very promising candidates to generate 
new drugs because of their high potency (pM-nM concentrations) and their fundamental 
roles in pathological processes. However, the therapeutic application of cytokines is limited, 
because several problems are encountered with their application in vivo (Schooltink and 
Rose-John 2002; Standiford 2000; Vilcek and Feldmann 2004). For instance, some cytokines 
are efficiently degraded in plasma by various enzymes and cytokines are rapidly excreted 
by the kidneys. Consequently their residence time in the body and thus the exposure to the 
diseased cells is short (plasma half life is often minutes), which does not favour an optimal 
biological efficacy. Another major problem is the occurrence of side effects. Because cytokine 
receptors are ubiquitously expressed in all organs, unusual high plasma concentrations of 
the cytokine can lead to (unwanted) effects in various organs.  
To overcome these problems, we use drug targeting techniques to selectively deliver the 
cytokine to a specific (diseased) cell (Allen and Cullis 2004; Beljaars, Meijer, Poelstra 2002). 
The challenge is to improve its distribution within the body and direct the cytokine to a cell 
of interest, while maintaining the biological activity of that particular cytokine after 
chemical modification. A conventional way to modify proteins is conjugation with poly-
ethylene glycol (PEG) (Jevsevar, Kunstelj, Porekar 2010). The attachment of PEG moieties 
improves the pharmacokinetics. That is, PEG substitution prevents rapid renal elimination 
which results in compounds with prolonged plasma concentrations, thereby making a 
reduced number of doses possible. For instance, PEGasys (PEGylated interferon 2a), an 
example of a PEGylated cytokine that is now commonly used to treat patients infected with 
viral hepatitis, is dosed once a week while the unmodified interferon is dosed daily. This 
leads to an improvement in the compliance and quality of life in patients with chronic 
diseases. The side effects, however, are not diminished after PEGylation.  
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Our strategy of active drug targeting, in contrast to the abovementioned PEGylation 
approach, aims to improve pharmacokinetics and efficacy while simultaneously avoiding 
side-effects by cell-specific delivery of the cytokine to the diseased cell via receptor-
mediated interaction. To that end, the cytokine is modified with homing devices that 
recognize receptors present on the diseased (target) cells. In the past, we designed sugars 
and receptor-recognizing peptides that interact with hepatic stellate cells (HSC) (Beljaars 
and others 1999; Beljaars and others 2000; Beljaars and others 2003). These cells play the 
central role in liver cirrhosis (Bataller and Brenner 2005; Friedman 2010; Schuppan and 
Afdhal 2008). Our newly designed homing devices displayed affinity for the mannose 6-
phosphate/insulin-like growth factor (M6P/IGF) II receptor, platelet derived growth factor 
(PDGF)- or collagen type VI receptors, which are all essential during stellate cell 
functioning in fibrogenesis, and upregulate in the diseased liver. 
Currently, it is accepted that liver cirrhosis is a fibrotic disease that is reversible (Iredale 
2007).  However, to date, no drug is marketed that is able to reverse the fibrotic process in 
patients (Pinzani, Rombouts, Colagrande 2005). The only treatment that is applied to these 
patients deals with the treatment of complications and with eradication of the cause (for 
instance removal of the hepatitis virus in case of HCV-induced cirrhosis). However, fibrosis 
often progresses to end-stage liver failure leaving a liver transplantation as the only 
available option. Therefore, worldwide research focuses on the identification of compounds 
that are able to reverse the disease, but unfortunately many potential interventions fail in 
clinical trials (Pinzani, Rombouts, Colagrande 2005). We hypothesize that this failure may be 
due to an inadequate pharmacokinetic profile of the potential drugs or due to the occurrence 
of side-effects of these drugs preventing the administration of effective doses, which may be 
solved by applying drug targeting techniques.  
The selective delivery of cytokines to the cells that control pathological processes is quite 
relevant. PEGylation of cytokines like interferon α, TNFα, and IL-2 has provided substantial 
benefits, but in that approach cytokines are not actively delivered to the site of action. In the 
present study, we will show an example of this second approach using the cytokine 
interleukin-10 (IL10). IL10 has potent immunosuppressive and anti-inflammatory effects  
(Di Marco and others 1999; Khan and others 2002; Kitching and others 2000; Oberholzer, 
Oberholzer, Moldawer 2002) and also direct antifibrotic properties in HSC (Cuzzocrea and 
others 2001; Demols and others 2002; Gloor and others 1998; Louis and others 1998; Louis 
and others 2003; Thompson and others 1998; Wang and others 1998). Several of these studies 
showed beneficial effects of IL10 therapies in animal models and clinical trials during 
various diseases. However, other studies demonstrated only a limited effect of IL10 or even 
showed disappointing results (Chadban and others 1997; Colombel and others 2001; 
Herfarth and Scholmerich 2002). This variable efficacy might be due to the low 
concentration of IL10 at the target sites. Recombinant IL10 is a low molecular weight protein 
that is rapidly cleared from the circulation through glomerular filtration. The plasma half-
life of IL10 is only 2 min (Rachmawati and others 2004). The ultimate concentrations at the 
site of action therefore could be too low to result in clear effects. Dose escalation of 
systemically administered IL10 leads to adverse effects due to its inherent biological actions 
(Fedorak and others 2000; Schreiber and others 2000). In accordance with this, clinical 
studies reported beneficial effects of long-term IL10 therapy to treat HCV-associated liver 
fibrosis but this was accompanied by an immunosuppressive action, as noted in a flare-up 
of the viral burden, and low therapeutic efficacy (Nelson and others 2000)(Meijer and others 
www.intechopen.com
Modification of Interleukin-10 with Mannose-6-Phosphate  
Groups Yields a Liver-Specific Cytokine with Antifibrotic Activity in Rats 
 
163 
2001). Liver-selective delivery of this cytokine may prevent these clinical problems and 
create biological effects within relevant cells.  
Upregulation of mannose-6-phosphate/IGF-II receptors during liver injury on HSC (de Bleser 
and others 1995) offers an excellent target for receptor-mediated antifibrotic drug delivery as 
shown with albumin substituted with mannose-6-phosphate groups (Beljaars and others 1999). 
We therefore modified IL10 with the sugar mannose-6-phosphate (M6P) to selectively deliver 
this cytokine to HSC in fibrotic livers (Rachmawati and others 2007). We showed that after 
modification of IL10 with mannose 6-phosphate (M6P) a compound was generated that binds 
to the M6P/IGF-II receptor which is highly present on activated HSC. Our chemically 
engineered cytokine, M6P-IL10, displayed good pharmacological activity in vitro in freshly 
isolated HSC. We now performed biodistribution studies of radiolabeled-M6P-modified IL10 
using gamma-camera techniques to examine the active delivery of this compound to the 
diseased tissue. Furthermore, we studied the pharmacological activities of this conjugate in 
rats at an early stage of liver fibrosis and compared this to the effects of unmodified IL10. 
2. Results 
2.1 Synthesis of M6P-IL10 
Mannose-6-phosphate-residues were coupled to the amino acid lysine in recombinant 
human IL10 as described (Rachmawati and others 2007). The product was first characterized 
by Western Blotting techniques using a rabbit polyclonal anti-IL10 antibody (Santa Cruz 
Biotechnology, USA). Western Blot analysis of unmodified IL10 yielded two bands 
corresponding to a molecular weight (MW) of 18.5 and 37 kD (fig.1) representing the 
monomeric and the homodimeric form of IL10 (Reineke and others 1998). The prepared 
conjugate M6P-IL10 revealed a shift in these bands: both bands had a higher MW (resp. 
approximately 20 and 40 kD) than unmodified IL10 indicating covalent binding of M6P to 
the cytokine.  
 
Fig. 1. Western blot analysis of M6P-IL10 and IL10. Note the increase in molecular weight of 
the monomeric (± 20 kD) and the homodimeric (± 40 kD) forms of M6P-IL10 compared with 
the monomeric and homodimeric forms of native IL10 (respectively, 18.5 kD and 37 kD). 
Mw marker IL-10 M6PIL-10 
20 kD 
40 kD
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2.2 Body distribution of IL10 and M6P-IL10 
To visualize the body distribution of IL10 and M6P-IL10 with a gamma camera, both 
proteins were labeled with Iodine-123 (123I). Fibrotic rats were monitored during the course 
of their disease by subjecting them to gamma camera analysis, just prior to BDL and one, 
two and three weeks after BDL (respectively, normal, BDL-1, BDL-2, and BDL-3, n=3). 
Anaesthetized rats were placed on a low-energy all-purpose collimator of a gamma-camera 
and received an intravenous tracer dose. The results are shown in figure 2. Already two min 
after iv injection of [123I]M6P-IL10, the gamma-camera detected high levels of radioactivity 
within the livers (white intensity) and low levels in the kidneys (yellow-red intensity). 
Hepatic levels of [123I]M6P-IL10 remained high for at least 30 min. The results of the 
distribution studies were similar in various stages of liver fibrosis (BDL-1, BDL- 2 and BDL-
3). In contrast, native [123I]IL10 rapidly accumulated in the kidneys (white intensity) with 
low uptake in livers (fig.2a),  which is in agreement with previous studies (Andersen and 
others 1999; Rachmawati and others 2004). 
Subsequently, we quantitatively measured the distribution of [125I]IL10 and [125I]M6P-IL10 ten 
minutes after intravenous injection in rats with end-stage liver fibrosis (BDL-3 weeks).  Native 
[125I]-IL10 accumulated in the kidneys in these rats (Fig 2b). Only, 15% and 30% of the dose 
was found in livers of normal and BDL-3 rats respectively. The rest was dispersed throughout 
the body or present in the blood. In contrast, [125I]M6P-IL10 accumulated for nearly 60% of the 
dose within the livers in BDL-3 rats. Uptake in kidneys was only 20%. Differences in blood- , 
liver- and kidney-concentrations between IL10 and M6P-IL10 were significant (p<0.05).  
 
Fig. 2. Organ Distribution of M6P-IL10 and IL10. A: Gamma-camera images of [123I]IL10 and 
[123I]M6P-IL10 distribution in BDL-1 rats. Pictures show an overlay of recordings from t=20 
to t=30 minutes after i.v. injection of radiolabeled proteins. The images show a high 
accumulation of M6P-IL10 in the liver (L) in contrast to IL10, which is mostly distributed to 
the kidneys (K). B: Quantitative measurement of organ uptake of [125I]-labeled IL10 (white 
bars) and M6P-IL10 (black bars) in BDL-3 rats 10 minutes after i.v. administration of the 
radiolabeled proteins. N = 3 per group (* p<0.05 compared with IL-10 distribution) 
2.3 Identification of target receptors 
(Modified) IL10 could not be detected within livers by immunohistochemistry, most likely 
due to the very low dose administered (2-2.5 μg). Therefore, several receptor antagonists 
were applied to identify the target receptors responsible for the uptake of the proteins in 
different organs in order to obtain information about the hepatocellular distribution. Rats 
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were pre-treated with either succinylated human serum albumin (sucHSA) to block the 
scavenger receptor, or with mannose-6-phosphate-HSA, to block the M6P/IGFII receptor. 
These receptor antagonists (i.v. dose of 5 mg/kg) were administered 5 min. prior to the i.v. 
injection of a tracer amount of radiolabeled IL10 or M6P-IL10. Control animals received pre-
treatment with unmodified HSA (5 mg/kg).  
Kidney accumulation of [125I]IL10 or [125I]M6P-IL10 was not influenced by administration of 
any of the proteins (fig. 3). Uptake of [125I]IL10 in the livers was also not influenced by any of 
the proteins, but remained  approximately 20% of the dose in all groups. However, liver 
uptake of M6P-IL10 was reduced from 54 ± 6% in rats receiving only M6P-IL10, to 29± 4% by 
sucHSA (p<0. 05) and to 24 ± 8% by M6P-HSA pre-administration (p<0.05). Co-administration 
of both sucHSA and M6P-HSA did not have an additive effect (24 ± 5% liver uptake). 
Unmodified HSA did not affect liver uptake of M6P-IL10 at all (57 ± 13% liver uptake). 
 
Fig. 3. Organ distribution of [125I]IL10 (fig. A) and [125I]M6P-IL10 (fig. B) in BDL-3 rats 10 
min. after i.v. administration of the radiolabeled proteins. Five min. before administration of 
these proteins, HSA, sucHSA, M6PHSA or the combination of two proteins was 
administered to test receptor specificity. Note that sucHSA and M6PHSA influenced liver 
uptake and blood concentrations of M6P-IL10, whereas IL10 distribution was not affected by 
any of the proteins. N=4-6 per group. * =p<0.05 compared with HSA pre-administration. 
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2.4 Effects of IL10 and M6P-IL10 in vitro 
The in vitro activities of IL10 and M6P-IL10 were studied in culture-activated primary HSC. 
The presence of IL10 receptors and M6P/IGFII-receptors on these cells was verified by 
immunohistochemical methods. No effect of IL10 or M6P-IL10 was found on HSC 
proliferation as assessed by Alamar blue assays (data not shown).  
We also examined type I collagen deposition in cultures of HSC treated with IL10 or M6P-
IL10 using immunostaining methods. Deposition of type I collagen was clearly detectable in 
HSC cultures at day-7 (fig 4A) and this staining was reduced in cultures treated for 24 hr 
with IL10 (Fig 4B) and in cultures treated with M6P-IL10 (fig 4C). 
 
Fig. 4. Type I collagen deposition in cultures of primary isolated rat HSC’s as detected with 
immunostaining methods. Collagen staining (using a goat polyclonal anti-collagen I antibody) 
is present on HSC’s after 7 days in culture (A, arrows). Deposition of collagen is attenuated by 
24 hr incubation with 12.5 ng/ml IL10 (B) or M6P-IL10 (C). Original magnification 200x.  
2.5 Effects of IL10 and M6P-IL10 in vivo 
2.5.1 Experimental design 
Bile duct ligated rats were randomly divided into three groups: BDL rats received either 
vehicle (PBS, N = 5), or IL10 (N = 5) or M6P-IL10 (N = 5). Untreated normal rats (N = 3) 
served as reference group. Animals received a bolus iv dose (8 μg/kg/day) of (modified-) 
IL10 at day 4, 5 and 6 after BDL. At day 7, animals were sacrificed and samples of blood and 
various organs were harvested. 
2.5.2 Effect of IL10 and M6P-IL10 on liver function 
Plasma levels of markers reflecting liver injury and cholestasis in BDL-1 rats receiving IL-10 
or M6PIL-10 were not significantly different from untreated BDL rats (table 1).  
2.5.3 Effect of IL10 and M6P-IL10 on inflammatory parameters 
To study the effects of IL10 and M6P-IL10 on inflammation, staining for reactive oxygen 
species (ROS)-production and IL10 receptor expression was performed. The number of 3,3'-
diaminobenzidine (DAB)-positive cells in the liver was high around necrotic areas and in 
portal areas. DAB staining reflects ROS production (Poelstra and others 1990) by activated 
neutrophils, eosinophils and macrophages.  
A B C 
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Parameters PBS-treated rats IL10-treated rats M6PIL-10-treated rats 
Alkaline Phosphatase 
(U/L) 
493.8 ± 71.2 476.2 ± 53.8 450.6 ± 16.13 
AST (U/L) 350.0 ± 166.6 354.0 ± 118.8 301.0 ± 109.64 
ALT (U/L) 92.2 ± 27.44 90.2 ± 24.9 84.0 ± 17.0 
Total bilirubin (mol/L) 191.2 ± 43.13 231.6 ± 21.9 194.8 ± 68.6 
GGT (U/L) 65.0 ± 56.0 74.0 ± 75.95 34.8 ± 23.34 
Table 1. Plasma levels of markers reflecting liver injury and cholestasis in BDL-1 rats treated 
with PBS, IL10 or M6P-IL10. Values represent the mean ± SD of 5 rats per group. 
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Fig. 5. Effect of IL-10- and M6PIL-10-treatment on the number of DAB-positive cells in livers 
of BDL-1 rats. Both treatments significantly reduced the number of DAB-positive cells in the 
portal areas compared with PBS-treated rats. *= p<0.05; **=p<0.01 
IL10 and M6P-IL10 strongly attenuated the staining for DAB (Fig. 5). Quantitative 
evaluation of this staining by counting the number of positive cells/area showed that DAB 
staining was reduced by 35% in rats receiving IL10 (p<0.05 compared with untreated BDL-1 
rats, Fig 5b), whereas the number of DAB-positive cells per area in M6P-IL10-treated rats 
was reduced by 74% compared with untreated rats (p<0.05). Thus, both IL10 and M6P-IL10 
exerted anti-inflammatory effects within the liver and M6P-IL10 was superior in this respect. 
Staining for IL10 receptors (with anti-IL-10 receptor IgG (Santa Cruz Biotech)) on liver 
sections of BDL-1 rats revealed occasional positive cells: some cells around the proliferating 
bile ducts and around hepatic arteries were positive. Based on the localization and the 
positivity for α-smooth muscle actin or HIS-48, these cells were identified as fibroblasts, 
HSC and neutrophils. In BDL-1 rats that received IL10, hepatic IL10 receptor expression was 
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strongly reduced, in particular around the portal areas (fig.6). In contrast, in BDL-1 rats 
receiving M6P-IL10, IL10 receptor expression was still present. 
 
Fig. 6. Intrahepatic staining for IL10 receptor expression in fibrotic livers. In PBS-treated 
BDL-1 rats, positive cells were found around bile ducts (fig. A, arrows). In rats treated with 
IL10, only occasional IL10 receptor-positive cells were found (fig. B) whereas the portal 
areas contained many IL10 receptor positive cells in BDL-1 rats treated with M6P-IL10 (fig. 
C). Original magnification 100x.  
2.5.4 Antifibrotic effects of IL10 and M6P-IL10 
Characteristic for fibrosis is deposition of extracellular matrix in tissues. Collagen type I and 
III are the most important extracellular matrix proteins present in a fibrotic liver. Therefore, 
we assessed the effect of M6P-IL10 and IL10 administration on the deposition of collagen. 
First, we evaluated the deposition of fibrous tissue by histochemical staining with Sirius Red 
(figure 7A). This staining was strongly enhanced in BDL-1 rats compared with normal rats. 
The portal-to-portal bridging was already apparent in the untreated group at this time 
point. However, in IL10-treated rats, the portal-portal fibrous bridges were observed in only 
one out of five rats and bridging was not seen in any of the M6P-IL10-treated rats. The 
matrix deposition around portal areas was clearly reduced by the treatments compared to 
untreated group. This reduction was confirmed by immunostaining for collagen type III 
using goat anti-collagen III IgG (SouternBiotech, USA) antibodies. The strong staining seen 
in BDL-1 rats was reduced by IL10 and M6P-IL10 (fig. 7B). 
With ImageJ software, the effects of IL10 and M6PIL10 on the deposition of fibrous tissue 
were quantified. In normal livers, 1.0 ± 0.45 % of the total liver area was positive for Sirius 
Red. This positive area increased to 4.6 ± 1.0% of the livers of BDL-1 rats (p<0.001 compared 
with normal rats, Fig. 7C).  In IL10-treated BDL-1 rats the Sirius Red-positive area per liver 
changed to 3.6 % ± 1.6 (not significant compared with untreated BDL-1 rats). In M6P-IL10-
treated BDL-1 rats, Sirius Red-staining changed to 3.4 ± 1.1 % of liver area (p< 0.05 
compared with untreated BDL-1 rats, Fig. 7C). The effect of IL10 and M6P-IL10 on the 
fibrotic process was also assessed by staging the lesions via a semiquantitative scoring 
system; the Histologic Activity Index-Knodell (Ishak and others 1995). Grading of the 
fibrotic lesions in these livers by the HAI-Knodell’s index revealed a reduction of the fibrotic 
index from 3.2 ± 0.8 in untreated BDL-1 rats to 2.6 ± 0.9 and 2.2 ± 0.45 (p<0.05) in rats 
receiving IL10 and M6P-IL10, respectively (fig. 7D). 
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Fig. 7. Collagen deposition in BDL rats after treatment with M6P-IL-10 or IL-10.  A. 
Representative photomicrographs of Sirius Red (fig. A) and collagen type III staining (fig. B) 
in livers of BDL-1 rats treated with PBS, IL-10 or M6PIL-10 (magnification 10x4). Figure C 
depicts the quantitative analysis of the Sirius Red stainings in the livers of the different 
groups as measured by Image J software. The individual values of each rat are shown in the 
graph. Figure D shows the semiquantitative grading of the fibrotic process in BDL-1 rats 
with the Histological Activity Index-Knodell method.  N=5 per group, * = p<0.05 compared 
with PBS-treated BDL rats. 
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Fig. 8. Representative photomicrographs of immunohistochemical staining for α-smooth 
muscle actin (αSMA) in livers of BDL-1 rats treated with PBS (fig. A) or IL10 (fig. B) or M6P-
IL10 (fig. C). Figure D depicts the quantitative analysis of the intrahepatic αSMA staining 
with Image J software (n=5 animals per group). *=p<0.05, Original magnification 100x. 
Subsequently, we evaluated the in vivo effects of M6P-IL10 and IL10 on -smooth muscle 
staining (-SMA), that reflects the proportion of activated HSC and myofibroblasts. These 
cells are responsible for the production of collagen. One week after BDL, staining for -SMA 
was highly increased around portal ducts and in fibrotic septa compared with normal rats. 
IL10 and M6P-IL10 clearly diminished this -SMA staining (fig.8). Quantitative evaluation 
of this staining using ImageJ software (fig.8B), demonstrated a significant reduction by 54% 
± 17% and 33% ± 19% after treatment with IL10 or M6P-IL10, respectively compared to PBS-
treated BDL rats (p<0.05).  
3. Conclusion/discussion  
This study demonstrates that chemical modification of a cytokine, in our study IL10 modified 
with M6P groups, leads to a compound with improved biodistribution and pharmacological 
activity in vivo in a rat model of liver fibrosis. M6P is a homing device with high affinity for the 
M6P/IGF-II receptor which is upregulated on the cell membrane of HSCs during liver diseases 
(de Bleser and others 1995). Upregulation of this receptor on HSC during liver fibrosis yields 
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an excellent target for receptor-mediated drug delivery. The delivery of antifibrotic 
compounds to the major pathogenic cells in the liver by modification with M6P groups is a 
rational and new approach to treat this chronic disease (Schuppan and Popov 2009).  
Chemical modification of a cytokine can influence the biological activity, in particular when 
essential amino acids necessary for interaction of the cytokine with its receptor are 
conjugated with homing devices or when the conformation of the protein is changed too 
much. Therefore, it is essential to test whether the prepared conjugate is pharmacologically 
active. In our study, we coupled several M6P groups to the lysine amino acids within the 
protein and some of these lysine-groups are present at the receptor-binding site of IL10 
(Reineke and others 1998). Attachment of M6P-residues to these groups might therefore 
affect the biological activities of IL10. Studies on culture-activated primary HSC in vitro 
showed that M6P-IL10 reduced collagen deposition by these cells (fig 4) indicating that 
IL10-related activities are still intact in the modified cytokine. There was no effect of M6P-
IL10 on HSC proliferation but native IL10 also did not affect growth of HSC. Previously, we 
demonstrated that M6P-IL10 was able to increase collagen degradation (by increasing the 
MMP13/TIMP ratio) in primary cultures of HSC (Rachmawati and others 2007). Based on its 
effects on collagen deposition, we conclude that M6P-IL10 is pharmacologically active 
within the target cell in vitro.  
The key concept in active drug targeting is that the distribution within the body is confined 
to the diseased organ/cell-types. This will lead to more optimal effects and less side effects 
because uptake in other organs is avoided. In pharmacokinetic terms, this means that the 
Volume of Distribution (Vd) is decreased. The presented results of gamma-camera imaging 
studies and the biodistribution studies with radiolabeled IL10 and M6P-IL10 indicate a 
preferential homing of the modified cytokine to the fibrotic liver. The shift in biodistribution 
of IL10 from the kidney to the liver after coupling of M6P is in accordance with the high 
liver uptake of M6P modified proteins found in previous studies with HSA as the core 
protein (Beljaars and others 1999; van Beuge and others 2011). These studies showed uptake 
of M6PHSA within HSC. The cells responsible for the uptake of M6P-IL10 within the liver 
could not be directly identified due to the low amount of cytokines administered. Both 
proteins are only available in the microgram scale and immunohistochemical detection of 
proteins requires injection of milligrams per rat. Therefore, receptor antagonists were 
applied to identify the target receptors. These studies indicated that liver uptake of M6P-
IL10 was receptor-mediated since the uptake was not attenuated by the control protein HSA 
whereas sucHSA and M6P-HSA, both ligands for receptors, significantly reduced its uptake. 
The fact that sucHSA and M6P-HSA both had an effect indicates that M6P-IL10 binds to at 
least two receptors: the scavenger receptor and the M6P/IGFII receptor, respectively. 
Involvement of the scavenger receptor, which recognizes strongly anionic compounds, can 
be explained by the negative charges introduced by phosphate groups (PO43-). This was also 
found in another study in which liposomes were modified with M6P sugars (Adrian and 
others 2006). The combination of M6PHSA and sucHSA did not completely block the liver 
uptake which suggests the involvement of yet another receptor, possibly the IL10 receptor 
which is also present in the liver (fig 6). Based on the expression of M6P/IGF II receptors, 
scavenger receptors and IL10 receptors, the putative target cells for M6P-IL10 are HSC’s, 
portal fibroblasts, endothelial cells, Kupffer cells and neutrophils within the liver. 
Antifibrotic effects of IL10 are anticipated in all these cells.  
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To test whether M6P-IL10 is effective in vivo, we now administered (modified-)IL10 to bile 
duct ligated rats after the initiation of the fibrotic process, i.e. from day 4 till day 7 after BDL. 
In this time frame, pro-inflammatory activity is high in the liver and fibrosis is initiated (39-
43). In addition, M6P/IGF-II receptor expression on HSC is enhanced at day 4 (Greupink 
and others 2006), which ensures targeting to this receptor at this time point. During the first 
week after BDL, enhanced IL10 receptor expression was noted (fig 6), also providing a 
rationale for the start of treatment at day 4.  
Treatment with IL-10 or M6P-IL10 had significant effects on the inflammatory activity within 
the liver. A reduction in the number of infiltrating cells as reflected by DAB-positive cells was 
noted. These data indicate that M6P-IL10 is pharmacologically active in vivo. Based on 
inflammatory cell influx, its effect may even be superior to native IL10. Of particular interest is 
the reduction in IL-10 receptor expression after treatment with IL10, but not after treatment 
with M6P-IL10. The down regulation of the target receptor during treatment is relevant for 
IL10-based therapies. This may contribute to the lack of effectiveness of such therapies 
(Chadban and others 1997; Colombel and others 2001; Herfarth and Scholmerich 2002).  
Next to the anti-inflammatory effects, we evaluated the effects of M6P-IL10 on fibrogenesis in 
vivo. The target cell of IL10 is the (activated) HSC, the extracellular matrix producing hepatic 
cell, and therefore antifibrotic effects are primarily anticipated in HSC and the most important 
feature in this respect is collagen deposition. Our results showed a clear reduction in collagen 
deposition in these livers after treatment with M6P-IL10 (figure 7). This reduction was 
established with various methods. The lack of portal-to-portal bridging was evident in nearly 
all the livers of the cytokine-treated animals. In addition, IL10 and M6P-IL10 also significantly 
reduced αSMA staining which reflects a reduction in the activation of HSC in these livers. 
These results indicate that our modified IL10 is pharmacologically active in vivo.   
Although cytokines are interesting compounds which may yield potent new drugs, so far 
only a relatively few are approved and clinically used. The number is still disappointing low 
regarding the large number of endogenous cytokines. The main reasons for this are the poor 
stability and poor pharmacokinetic profile of cytokines. To overcome these pharmacokinetic 
problems, we apply drug targeting techniques to selectively deliver the cytokine to a specific 
(diseased) cell. In the current study, we demonstrate the possibilities of this strategy with 
successful in vivo application of a modified IL10. Recently, we also reported on the cell-
specific delivery of another very interesting cytokine with antifibrotic activities, that is 
interferon-gamma (IFNγ) (Bansal and others 2011). This study shows that HSC-targeted 
IFNγ, in contrast to unmodified IFNγ, blocked liver fibrogenesis in a chronic CCL4 mice 
model of liver fibrosis, by specifically acting on the key pathogenic cells within the liver. 
Furthermore, we clearly demonstrated that the targeted IFNγ was devoid of side effects. In 
addition, others show beneficial effects of a targeted cytokine by means of coupling receptor 
specific ligands to the cytokine (Curnis and others 2000; Curnis and others 2005; Fournier, 
Aigner, Schirrmacher 2011; Jazayeri and Carroll 2008; Nissim and others 2004) often 
focussing on the treatment of tumours. These approaches may lead to a more optimal use of 
cytokines for therapeutic purposes. 
In summary, we demonstrated potent pharmacological effectivity of a novel liver-specific 
form of the cytokine IL10. After conjugation with M6P, the novel cytokine efficiently 
accumulates in the liver and attenuates the fibrotic process in vivo. Further dose-response 
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studies are required to examine whether M6P-IL10 is more effective than the native product 
and exerts less adverse effects. Furthermore, targeting of potentially interesting cytokines to 
the liver is promising and it may lead to the generation of a therapeutic antifibrotic 
compound which has not been realized so far.  
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